– BrightInsight raises $25M in Series A funding co-led by New Leaf Venture Partners and Eclipse Ventures to further enhance the functionality of its BrightInsight Platform and accelerate global commercialization efforts.
– BrightInsight platform enables regulated drugs, devices and SaMDs to ingest and analyze data and deploy regulated recommendations and insights back to patients and providers
BrightInsight, San Jose, CA-based global regulated digital health platform for biopharma and MedTech, announced today it has raised $25M in Series A funding. The funding was co-led by New Leaf Venture Partners and Eclipse Ventures.
Contrary to the traditional siloed approach in healthcare, patients, payers, physicians, and caregivers are all demanding to see a more holistic view of a patient’s health data. Integrating data across devices, therapies and health IT systems, including EHRs, will enable more proactive, informed care.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Founded in 2018, The BrightInsight Platform is a medical-grade Internet of Things (IoT) platform built under a robust ISO 13485:2016 certified Quality Management System to support and optimize regulated drugs, devices, and software through integrated data and actionable insights. It also enables our customers to increase patient adherence and engagement.
Expansion Plans
The funding enables BrightInsight to further enhance the functionality of its BrightInsight Platform and accelerate global commercialization efforts for the leading global regulated digital health platform serving biopharma and MedTech customers. BrightInsight will also further integrate its platform into the broader healthcare ecosystem, including Electronic Health Records (EHRs), payers and disease management programs.
Recent Traction/Milestones
Having achieved the utmost privacy, security, regulatory and quality certifications, BrightInsight was selected as Novo Nordisk’s global digital health partner to develop innovative solutions for diabetes patients. Additionally, the company announced the launch of a dosing calculator to treat patients with Hemophilia A, which was sponsored by F. Hoffmann-La Roche.
In the past year, the award-winning BrightInsight Platform was selected as the “Best IoT Healthcare Platform” in the 2019 MedTech Breakthrough Awards, the “2018 Google Cloud Partner of the Year for Healthcare and Life Sciences,” and was featured as the cover story for CIOReview Magazine’s “20 Most Promising Biotech Solution Providers 2019.”
“Since the launch in 2018, our BrightInsight Platform has become the leading global regulated digital health platform for the world’s top biopharma and medtech companies,” said Kal Patel, MD, CEO and Co-Founder, BrightInsight. “Our investors have strong pedigrees in healthcare as well as software and technology, which clearly validates our success thus far. This financing enables us to continue to invest in our differentiated platform while also integrating our solutions into the broader healthcare ecosystem globally.”
Date: September 10, 2019
Source: BioPortfolio
